INMED PHARMACEUTICALS INC. Operating Lease, Right-of-Use Asset, Amortization Expense
INMED PHARMACEUTICALS INC. (INM) reported Operating Lease, Right-of-Use Asset, Amortization Expense of $503.08 thousand for the 12-month period ending 2026-06-30, per its S-4/A filed 2026-09-09.
Financial Statements › Cash Flow › Operating Activities
us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense · last filed 2026-09-09
- INMED PHARMACEUTICALS INC. operating lease, right-of-use asset, amortization expense for the quarter ending 2026-06-30 was $211.84K, a 170.45% increase year-over-year.
- INMED PHARMACEUTICALS INC. operating lease, right-of-use asset, amortization expense for the quarter ending 2026-03-31 was $82.95K, a 7.34% increase year-over-year.
- INMED PHARMACEUTICALS INC. operating lease, right-of-use asset, amortization expense for the quarter ending 2025-12-31 was $104.82K, a 38.14% increase year-over-year.
- INMED PHARMACEUTICALS INC. operating lease, right-of-use asset, amortization expense for the quarter ending 2025-09-30 was $103.48K, a 14.47% increase year-over-year.
- INMED PHARMACEUTICALS INC. operating lease, right-of-use asset, amortization expense for fiscal 2023 was $393.75K, a 20.73% increase from fiscal 2022.
- INMED PHARMACEUTICALS INC. operating lease, right-of-use asset, amortization expense for fiscal 2022 was $326.13K.
| Period end | Operating Lease, Right-of-Use Asset, Amortization Expense 3 month | Operating Lease, Right-of-Use Asset, Amortization Expense 6 month | Operating Lease, Right-of-Use Asset, Amortization Expense 9 month | Operating Lease, Right-of-Use Asset, Amortization Expense 12 month | Operating Lease, Right-of-Use Asset, Amortization Expense 12 month as first filed |
|---|---|---|---|---|---|
| 2026-06-30 | $211.84K derived: S-4/A 12 month − S-4 9 month · filed 2026-09-09 | $294.79K derived: sum of 2 quarters · filed 2026-09-09 | $399.61K derived: sum of 3 quarters · filed 2026-09-09 | $503.08K S-4/A · filed 2026-09-09 | |
| 2026-03-31 | $82.95K derived: S-4 9 month − 10-Q 6 month · filed 2026-07-02 | $187.77K derived: sum of 2 quarters · filed 2026-07-02 | $291.25K S-4 · filed 2026-07-02 | $369.57K derived: sum of 4 quarters · filed 2026-09-09 | |
| 2025-12-31 | $104.82K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-02-11 | $208.30K 10-Q · filed 2026-02-11 | $286.63K derived: sum of 3 quarters · filed 2026-09-09 | $363.90K derived: sum of 4 quarters · filed 2026-09-09 | |
| 2025-09-30 | $103.48K 10-Q · filed 2025-11-06 | $181.81K derived: sum of 2 quarters · filed 2026-09-09 | $259.09K derived: sum of 3 quarters · filed 2026-09-09 | $334.96K derived: sum of 4 quarters · filed 2026-09-09 | |
| 2025-06-30 | $78.33K derived: S-4/A 12 month − S-4 9 month · filed 2026-09-09 | $155.61K derived: sum of 2 quarters · filed 2026-09-09 | $231.48K derived: sum of 3 quarters · filed 2026-09-09 | $321.88K S-4/A · filed 2026-09-09 | |
| 2025-03-31 | $77.28K derived: S-4 9 month − 10-Q 6 month · filed 2026-07-02 | $153.15K derived: sum of 2 quarters · filed 2026-07-02 | $243.56K S-4 · filed 2026-07-02 | $340.65K derived: sum of 4 quarters · filed 2026-07-02 | |
| 2024-12-31 | $75.88K 10-Q · filed 2025-02-12 | $166.28K 10-Q · filed 2026-02-11 | $263.37K derived: sum of 3 quarters · filed 2026-07-02 | $359.29K derived: sum of 4 quarters · filed 2026-07-02 | |
| 2024-09-30 | $90.40K 10-Q · filed 2025-11-06 | $187.50K derived: sum of 2 quarters · filed 2026-07-02 | $283.41K derived: sum of 3 quarters · filed 2026-07-02 | $376.50K derived: sum of 4 quarters · filed 2026-07-02 | |
| 2024-06-30 | $97.09K derived: S-4 12 month − 10-Q 9 month · filed 2026-07-02 | $193.01K derived: sum of 2 quarters · filed 2026-07-02 | $286.09K derived: sum of 3 quarters · filed 2026-07-02 | $384.92K S-4 · filed 2026-07-02 | |
| 2024-03-31 | $95.92K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-05-12 | $189.00K derived: sum of 2 quarters · filed 2025-05-12 | $287.82K 10-Q · filed 2025-05-12 | ||
| 2023-12-31 | $93.08K 10-Q · filed 2025-02-12 | $191.91K 10-Q · filed 2025-02-12 | |||
| 2023-09-30 | $94.53K 10-Q · filed 2024-11-14 | ||||
| 2023-06-30 | $393.75K 10-K · filed 2024-09-30 | ||||
| 2022-12-31 | $90.39K 10-Q · filed 2024-02-13 | $197.77K 10-Q · filed 2024-02-13 | |||
| 2022-09-30 | $99.46K 10-Q · filed 2023-11-14 | ||||
| 2022-06-30 | $326.13K 10-K · filed 2023-09-29 | $728.12K 10-K · filed 2022-09-23 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Apimeds Pharmaceuticals US, Inc. (APUS) | United States | $0.008B | |
| Ensysce Biosciences, Inc. (ENSC) | United States | $0.008B | -0.37 |
| CNS Pharmaceuticals, Inc. (CNSP) | United States | $0.007B | |
| EXICURE, INC. (XCUR) | United States | $0.008B | -1.54 |
| Acurx Pharmaceuticals, Inc. (ACXP) | United States | $0.007B | -0.97 |
| SOLIGENIX, INC. (SNGX) | United States | $0.008B | |
| Imunon, Inc. (IMNN) | United States | $0.008B | -0.56 |
| SYNLOGIC, INC. (SYBX) | United States | $0.007B | |
| Bolt Biotherapeutics, Inc. (BOLT) | United States | $0.007B | -0.26 |
| Enveric Biosciences, Inc. (ENVB) | United States | $0.007B | -0.63 |